New research from the University of Virginia School of Medicine speaks to the benefits of a COVID-19 booster. Credit: UVA Health New research from the...
For a long time, the world of genetic sequencing has been largely dominated by one company, namely, Illumina. Molly He helped design and drive forward...
MUSC Hollings Cancer Center oncologists found that using a combination monoclonal antibody (tixagevimab-cilgavimab) against the SARS-CoV-2 spike protein...
Less known to the general public, mucosal vaccination via the mucus membranes could provide robust protection against SARS-CoV-2 infections. Immune cells...
While RSV can become severe for any child, it poses a particularly serious threat for the youngest babies and for high-risk children.
During the 1918 flu pandemic, white people died at similar rates to Black Americans, according to a new study – a very different pattern than what...
The incredibly fast spread of COVID-19 throughout the world brought to light a very important fact: we need better methods to diagnose infectious diseases...
An effective nasal vaccine could stop the virus that causes COVID-19 right at its point of entry. But devising one that works has been a challenge...
Reports from China indicate BF.7 is quicker to transmit and has greater capacity to escape prior immunity than other omicron subvariants. But we shouldn’t...
We’re in a better position compared with 2020 and 2021, but the pandemic isn’t over yet.
COVID-19 and its latest Omicron strains continue to cause infections across the country as well as globally. Serology (blood) and molecular tests are the...
A review of the latest executive moves in the pharma industry over the past several months.
New research shows that the closest bat virus relatives of the human Middle-East Respiratory Syndrome (MERS) coronavirus efficiently bind to bat ACE2 receptors...
Sorrento Therapeutics’ yearslong battle with NantCell and NANTibody has come to an arbitration award, but additional legal proceedings centered around...
NEW YORK and LA JOLLA, CA—While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy being...
FOR RELEASE AT: Thursday, December 1, at 2 p.m. US ET Credit: UNC School of Medicine FOR RELEASE AT: Thursday, December 1, at 2 p.m. US...
With the Biotechnology space rotating toward a more acquisition friendly dynamic, investors may benefit from a studied focus on likely takeout candidates...
Latest research findings show that vaccine-elicited neutralizing antibodies against SARS-CoV-2 are mostly directed against one of the two main domains...
The expanded platform will enable Oxford-based Exscientia to develop next-generation therapeutic antibodies through generative AI design—from computationally...
Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure The post Touring Chiesi’s vision for...
With the help of an AI, researchers at Chalmers University of Technology, Sweden, have succeeded in designing synthetic DNA that controls the cells’...
Are the currently approved antibody therapies used to treat individuals at increased risk for severe COVID-19 disease also effective against currently...
To create the best cold chain for a therapy, bioprocessors need to plan ahead. Product challenges directly impact biologics, and that’s the focus when...
A team of synthetic biologists at the Hong Kong University of Science and Technology (HKUST) has recently discovered a way that could increase synthetic...
Using a Nobel Prize-winning technique called cryo-EM, researchers were able to identify potential areas on the hepatitis C virus that a vaccine could ...
Respiratory viruses are hitting young children and infants particularly hard this fall and winter season, and experts don’t yet know exactly why.
Respiratory syncytial virus may be common, but it can lead to severe infection in some children.
Respiratory viruses are hitting young children and infants particularly hard this fall and winter season, and experts don’t yet know exactly why.
LA JOLLA—Seven researchers at La Jolla Institute for Immunology (LJI) have been named to the 2022 Highly Cited List, released today by Clarivate. This...
Nascent Biotech Inc. (OTCMKTS:NBIO) is an emerging player in the $4 billion oncology drug development space. NBIO is early-stage – its flagship drug...